Sign in
Taking people in United StatesNo phase

The APS Phenotyping Study

Key facts

Who runs it
Vanderbilt University Medical Center
Where
Ann Arbor, Baltimore, Chicago, Cincinnati, Denver, Durham, Fresno, Loveland, Murray, Nashville, Palo Alto, Philadelphia, Salt Lake City, San Francisco, and St Louis, United StatesSee the 20 sites
Trial code
Status
Recruiting
People taking part
4,000 people, planned
Started
25 Jul 2024
Expected to end
30 Apr 2029
Type of study
Observational, 3 groups
Treatments tested
  • Blood collection
  • Urine Collection
  • Nasal, oral, and rectal swabs
  • Stool collection
  • Heat Moisture Exchange Filter collection
  • Tracheal Aspirate sample collection
  • Non-bronchoscopic bronchoalveolar lavage (NBBAL)
  • Surveys
  • Short physical performance battery
  • Hand grip strength
  • CNS Vital Signs
  • Muscle Ultrasound
  • Muscle Strength
  • Spirometry
  • Lung Diffusion Testing (DLCO)
  • Chest CT Scan
Record updated
20 February 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • To be eligible for enrollment, a patient must meet all the following inclusion criteria at the time of the first study-specified biospecimen collection (Time 0):
  • Age ≥ 18 years old
  • Admitted (or planned to be admitted) to an intensive care unit (ICU) or other in-patient hospital location where IV vasopressors or advanced respiratory support (invasive mechanical ventilation, non-invasive ventilation, or high flow nasal cannula) are routinely provided (referred to as an "eligible unit.")
  • Acute cardiovascular or pulmonary organ dysfunction defined by meeting at least one of the two criteria below:; New receipt of invasive mechanical ventilation, non-invasive ventilation, high flow nasal cannula, or supplemental oxygen at a flow rate of ≥ 6 lpm for acute hypoxemia; Patients who use chronic oxygen therapy are eligible to participate if they are receiving at least 6 lpm higher than their baseline oxygen requirement (e.g., a patient on 3 lpm O2 at baseline is eligible if they require ≥9 lpm for hypoxemia) or are started on advanced respiratory support (invasive mechanical ventilation, non- invasive ventilation, or high flow nasal cannula); Receipt of intravenous infusion of a vasopressor medication for at least one hour
  • Acute cardiovascular or pulmonary organ dysfunction (inclusion criterion #3) is attributed to an acute inflammatory condition, including but not limited to any of the following:; Any infection including pneumonia; Aspiration pneumonitis; Pancreatitis; Auto-inflammatory condition such as:; Hemophagocytic lymphohistiocytosis; Suspected acute rheumatologic or auto-immune disease with pulmonary or cardiovascular manifestations; Suspected cryptogenic organizing pneumonia presenting acutely; Suspected diffuse alveolar hemorrhage; Suspected acute anaphylaxis; Suspected acute pulmonary drug toxicity

Who cannot take part

  • Patient had out-of-hospital cardiac arrest leading to this hospitalization
  • Presence of tracheostomy for respiratory failure
  • Home invasive mechanical ventilation or non-invasive ventilation (except patients with non-invasive ventilation prescribed as a treatment for a sleep disorder may participate)
  • Suspected cause of the patient's acute cardiovascular and/or pulmonary dysfunction (inclusion criterion #3) is an alternative condition (not ARDS, pneumonia, or sepsis), including but not limited to the list below:; Drug overdose (without aspiration, lung injury, pneumonia, or infection); Trauma (without aspiration, pneumonia, or infection); Chronic lung disease without suspected infection, aspiration, or inflammation; Asthma, chronic obstructive pulmonary disease (COPD), sarcoidosis, interstitial lung disease, neuromuscular respiratory failure; Status epilepticus; Acute pulmonary embolism; Acute decompensated heart failure; Diabetic ketoacidosis; Acute stroke or intracranial hemorrhage; Acute bleeding (GI bleeding, post-procedural bleeding, hemolysis); Cytokine release syndrome due to chemotherapy
  • Inability or unwillingness to complete study-specified blood draws, for example, due to local policies about hemoglobin thresholds for research blood draws
  • To be eligible for enrollment, a patient must not meet any of the following exclusion criteria at the time of the first study-specified biospecimen collection (Time 0):
  • Patient/legally authorized representative (LAR) declines participation
  • Acute cardiovascular or pulmonary organ dysfunction (inclusion criterion #3) has been present for > 48 hours
  • Patient has been in an eligible unit (inclusion criterion #2) for more than 120 hours (five days)
  • Patient is no longer expected to meet the acute cardiovascular or pulmonary organ dysfunction inclusion criterion (inclusion criterion #3) 24 hours after enrollment
  • Patient desires comfort measures only
  • Patient is a prisoner
  • Residence immediately before this hospitalization in a long-term acute care facility

Where in United States

  • University of MichiganAnn Arbor, United StatesContact: Robert Hyzy, MDTaking people
  • Johns Hopkins UniveristyBaltimore, United StatesContact: Dale Needham, MD, PhDTaking people
  • Northwestern Memorial HospitalChicago, United StatesContact: Richard Wunderink, MDTaking people
  • University of ChicagoChicago, United StatesContact: Krysta Wolfe, MDTaking people
  • University of CincinnatiCincinnati, United StatesContact: R. Duncan Hite, MDTaking people
  • Denver Health and Hospital AuthorityDenver, United StatesContact: Jason Mansoori, MDTaking people
  • National Jewish HealthDenver, United StatesContact: William Janssen, MDTaking people
  • University of Colorado DenverDenver, United StatesContact: Marc Moss, MDTaking people
  • Duke UniversityDurham, United StatesContact: Christina Barkauskas, MDTaking people
  • Fresno Community Hospital and Medical CenterFresno, United StatesContact: Eyad Almasri, MDTaking people
  • UC Health Medical Center of the RockiesLoveland, United StatesContact: Eric Stevens, MDTaking people
  • Intermountain Medical CenterMurray, United StatesContact: Samuel Brown, MD, MSTaking people
  • Meharry Medical CollegeNashville, United StatesContact: Richard Freemont, MDTaking people
  • Vanderbilt University Medical CenterNashville, United StatesContact: Wesley H. Self, MDTaking people
  • Stanford UniversityPalo Alto, United StatesContact: Angela Rogers, MDTaking people
  • University of PennsylvaniaPhiladelphia, United StatesContact: Nuala Meyer, MD, MSTaking people
  • University of UtahSalt Lake City, United StatesContact: Estelle Harris, MDTaking people
  • San Francisco General HospitalSan Francisco, United StatesContact: Carolyn Hendrickson, MD, MPHTaking people
  • University of California San FranciscoSan Francisco, United StatesContact: Carolyn Calfee, MDTaking people
  • Washington University School of MedicineSt Louis, United StatesContact: Pratik Sinha, MBChB, PhDTaking people

About the trial

What the trial wants to find out

The goal of the observational APS phenotyping study is to better understand risk factors, potential biomarkers, length and severity of illness, and recovery for adults with ARDS, pneumonia, and/ or sepsis. This study will also generate a biobank of specimens collected from these patients that will be available to investigators for future studies of ARDS, sepsis, and/or pneumonia.

The 3 groups in the trial

  • Cohort A (full study protocol - written informed consent)

    Cohort A is the cohort of APS study participants who have provided written informed consent for participation in the APS phenotyping study. Cohort A may participate in all study procedures in the APS phenotyping study.

    Treatment: Blood collection, Urine Collection, Nasal, oral, and rectal swabs, Stool collection, Heat Moisture Exchange Filter collection, Tracheal Aspirate sample collection, Non-bronchoscopic bronchoalveolar lavage (NBBAL), and Surveys

  • Cohort B (alteration study protocol - alteration of informed consent)

    Cohort B is the cohort of APS study participants who are enrolled in the study under alteration of informed consent. Cohort B will participate in a modified set of procedures which omits procedures considered greater than minimal risk.

    Treatment: Blood collection, Urine Collection, Nasal, oral, and rectal swabs, Stool collection, Heat Moisture Exchange Filter collection, and Tracheal Aspirate sample collection

  • Long-term Outcomes Cohort

    The Long-term Outcomes Cohort consists of a subset of participants with written informed consent for study participation (Cohort A) who complete in-person post-hospital study assessments. These in-person study visits are scheduled at 3- and 12-months after initial enrollment in the hospital. Interventions/exposures are denoted for this group for study procedures that are completed during an in-person post-hospital visit.

    Treatment: Blood collection, Nasal, oral, and rectal swabs, Stool collection, Short physical performance battery, Hand grip strength, CNS Vital Signs, Muscle Ultrasound, Muscle Strength, Spirometry, Lung Diffusion Testing (DLCO), and Chest CT Scan

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The ARDS, Pneumonia, and Sepsis (APS) Consortium: A Prospective Observational Study to Evaluate Phenotypes
Publications
Record updated
20 February 2026